(Q38116751)

29 August 2017

Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy (English)

1 reference

29 August 2017

1 reference

Kevin L Winthrop

1

1 reference

29 August 2017

Michael Iseman

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

25 June 2013

1 reference

Nature Reviews Rheumatology

29 August 2017

1 reference

29 August 2017

9

1 reference

29 August 2017

9

1 reference

29 August 2017

524-531

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2013.82

29 August 2017

0 references

cites work

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

The mortality of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Perturbation of the T cell repertoire in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Death rates and causes of death in patients with rheumatoid arthritis: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

The problem of choice: current biologic agents and future prospects in RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Back to the future: oral targeted therapy for RA and other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Preventing and treating biologic-associated opportunistic infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Update on the epidemiology of pulmonary nontuberculous mycobacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

An outbreak of mycobacterial furunculosis associated with footbaths at a nail salon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Pulmonary disease associated with nontuberculous mycobacteria, Oregon, USA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Spatial clusters of nontuberculous mycobacterial lung disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Mycobacterial diseases and antitumour necrosis factor therapy in USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Nontuberculous mycobacterial infection: CT scan findings, genotype, and treatment responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis. Prospective study in 75 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Glucocorticoid use, other associated factors, and the risk of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Environment or host?: A case-control study of risk factors for Mycobacterium avium complex lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Integrated safety in tocilizumab clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Tuberculosis associated with therapy against tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Screening for tuberculosis infection prior to initiation of anti-TNF therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Adalimumab treatment of life-threatening tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Serious infections with antirheumatic therapy: are biologicals worse?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

NRAMP1 gene polymorphism and susceptibility to nontuberculous mycobacterial lung diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Infection in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Modulation of CD28 expression with anti-tumor necrosis factor α therapy in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Disseminated Mycobacterium avium complex in non-human immunodeficiency virus-infected pediatric patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Peritonitis due to a mycobacterium chelonei-like organism associated with intermittent chronic peritoneal dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

The Prevalence of Tuberculosis and Positive Tuberculin Skin Tests in a Steroid-Treated Asthmatic Population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Reversion and reconversion rate of tuberculin skin reactions in correction with the use of prednisone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Increased risk of nontuberculous mycobacterial infection in asthmatic patients using long-term inhaled corticosteroid therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Minimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

You can't always get what you want, but if you try sometimes (with two tests--TST and IGRA--for tuberculosis) you get what you need

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Decreased cytokine production in patients with nontuberculous mycobacterial lung disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Low in vitro production of interferon-gamma and tumor necrosis factor-alpha in HIV-seronegative patients with pulmonary disease caused by nontuberculous mycobacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.82

Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis.

31 March 2020

1 reference

12 December 2020

Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism.

1 reference

12 December 2020

Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans

1 reference

12 December 2020

Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model

1 reference

12 December 2020

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

1 reference

12 December 2020

Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy

1 reference

12 December 2020

Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-α antibody in mice

1 reference

12 December 2020

Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2013.82

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference